Michael R Holbrook
Overview
Explore the profile of Michael R Holbrook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3845
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Alfson K, Eaton B, Mattix M, Goez-Gazi Y, Holbrook M, et al.
Molecules
. 2025 Feb;
30(4).
PMID: 40005201
Algal lectin Griffithsin (GRFT) is a well-known mannose-binding protein which has broad-spectrum antiviral activity against several important infectious viruses including HIV, HCV, and SARS-CoV-2. Therefore, GRFT has been brought great...
2.
Hastie K, Salie Z, Ke Z, Halfmann P, DeWald L, McArdle S, et al.
Nat Commun
. 2025 Feb;
16(1):1293.
PMID: 39900911
Monoclonal antibodies (mAbs) against Ebola virus (EBOV) glycoprotein (GP) are the standard of care for Ebola virus disease (EVD). Anti-GP mAbs targeting the stalk and membrane proximal external region (MPER)...
3.
Wang L, Seravalli J, Eaton B, Liu Y, Holbrook M, Lan W, et al.
Mar Drugs
. 2025 Jan;
23(1).
PMID: 39852525
Filoviruses, mainly consisting of the two genera of and , are enveloped negative-strand RNA viruses that can infect humans to cause severe hemorrhagic fevers and outbreaks with high mortality rates....
4.
Wang W, Bhushan G, Paz S, Stauft C, Selvaraj P, Goguet E, et al.
J Virol
. 2024 Oct;
98(11):e0094824.
PMID: 39365051
Antigenic assessments of SARS-CoV-2 variants inform decisions to update COVID-19 vaccines. Primary infection sera are often used for assessments, but such sera are rare due to population immunity from SARS-CoV-2...
5.
Cong Y, Dixit S, Perry D, Huzella L, Kollins E, Byrum R, et al.
Antiviral Res
. 2024 Aug;
230:105987.
PMID: 39147143
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and onset of the coronavirus disease-19 (COVID-19) pandemic led to an immediate need for therapeutic treatment options. Therapeutic antibodies were developed...
6.
Dickey T, Salinas N, Patel P, Orr-Gonzalez S, Ouahes T, McAleese H, et al.
Antiviral Res
. 2024 Jun;
228:105937.
PMID: 38901738
Most COVID-19 vaccines contain the SARS-CoV-2 spike protein as an antigen, but they lose efficacy as neutralizing antibody titers wane and escape variants emerge. Modifying the spike antigen to increase...
7.
Wang W, Bhushan G, Paz S, Stauft C, Selvaraj P, Goguet E, et al.
bioRxiv
. 2024 May;
PMID: 38712124
Antigenic assessments of SARS-CoV-2 variants inform decisions to update COVID-19 vaccines. Primary infection sera are often used for assessments, but such sera are rare due to population immunity from SARS-CoV-2...
8.
Ford E, Mayer-Blackwell K, Jing L, Laing K, Sholukh A, St Germain R, et al.
Nat Immunol
. 2023 Dec;
25(1):166-177.
PMID: 38057617
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hybrid immunity is more protective than vaccination or previous infection alone. To investigate the kinetics of spike-reactive T (T) cells from SARS-CoV-2 infection...
9.
Liu D, Pahar B, Perry D, Xu H, Cooper T, Huzella L, et al.
Am J Pathol
. 2023 Sep;
193(12):2031-2046.
PMID: 37689386
The pathophysiology of long-recognized hematologic abnormalities in Ebolavirus (EBOV) disease (EVD) is unknown. From limited human sampling (of peripheral blood), it has been postulated that emergency hematopoiesis plays a role...
10.
Stein S, Platt A, Teague H, Anthony S, Reeder R, Cooper K, et al.
J Infect Dis
. 2023 Aug;
228(Suppl 7):S635-S647.
PMID: 37652048
Background: Existing models of Ebola virus infection have not fully characterized the pathophysiology of shock in connection with daily virologic, clinical, and immunologic parameters. We implemented a nonhuman primate critical...